Microtubule inhib 
Welcome,         Profile    Billing    Logout  
 126 Companies  198 Products   198 Products   347 Diseases   949 Trials   31466 News 
1185 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Elahere (mirvetuximab soravtansine-gynx) / AbbVie
NCT05622890: A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer

Recruiting
3
35
RoW
Mirvetuximab Soravtansine, IMGN853, MIRV
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
04/23
12/23
MIRASOL, NCT04209855 / 2019-003509-80: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
Jan 2023 - Dec 2023: Market entry in ex-US for platinum-resistant ovarian cancer
Hourglass Jan 2023 - Mar 2023 : Top-line data from MIRASOL trial for high-grade epithelial ovarian cancer
Hourglass Jul 2022 - Sep 2022 : Approval for high-grade epithelial ovarian cancer (based on MIRASOL trial)
Completed
3
453
Europe, Canada, US, RoW
Mirvetuximab Soravtansine, MIRV, IMGN853, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
AbbVie, Gynecologic Oncology Group, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/23
08/24
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
520
Europe, Canada, Japan, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
04/29
04/29
2018-004207-39: Mirvetuximab Soravtansine in patients with high expression of folate receptor alpha in their tumor and recurrent ovarian cancer

Not yet recruiting
2
136
Europe
Mirvetuximab Soravtansine, Powder and solvent for concentrate for solution for infusion, Solution for infusion, Capsule, hard, Film-coated tablet, , Caelyx, Carboplatin Kabi, Paclitaxel-GRY®, Gemedac®, Zejula, Lynparza, Rubraca
AGO Research GmbH, ImmunoGen, Inc.
This trial evaluates the efficacy and safety of Mirvetuximab soravtansine (IMGN853) plus Carboplatin chemotherapy in FRα high patients with recurrent ovarian cancer who are eligible for platinum-based chemotherapy., Safety and efficacy for carboplatin with Mirvetuximab soravtansine (IMGN853) compared to carboplatin combination chemotherapy, Diseases [C] - Cancer [C04]
 
 
2021-003592-34: c Un estudio para probar mirvetuximab soravtansina en mujeres con cánceres epiteliales de ovario, peritoneales primarios o de trompa de Falopio sensibles al platino.

Not yet recruiting
2
75
Europe
mirvetuximab soravtansine, IMGN853, Concentrate for solution for injection/infusion, Pred Forte
ImmunoGen, Inc., IMMUNOGEN, INC., ImmunoGen, Inc.
Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression Cánceres epiteliales de ovario, peritoneales primarios o de trompa de Falopio recurrentes, sensibles al platino y con alta expresión del receptor de folatos alfa, Cancer of ovary and related organs Cáncer de ovario y órganos afines, Diseases [C] - Cancer [C04]
 
 
NCT03835819: A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

Active, not recruiting
2
18
US
Pembrolizumab, Keytruda, IMGN853, Mirvetuximab soravtansine, Elahere
Dana-Farber Cancer Institute, ImmunoGen, Inc., Merck Sharp & Dohme LLC
Endometrial Cancer
06/24
05/27
NCT03832361: Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

Recruiting
2
50
US
IMGN853, mirvetuximab soravtansine
Alessandro Santin, ImmunoGen, Inc.
Endometrial Cancer
10/25
10/28
MIROVA, NCT04274426 / 2018-004207-39: Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Active, not recruiting
2
136
Europe
Carboplatin, Pegylated liposomal doxorubicin (PLD), Gemcitabine, Paclitaxel, Mirvetuximab Soravtansine
AGO Research GmbH, ImmunoGen, Inc.
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
12/25
12/26
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
Hourglass Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
Hourglass Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
Hourglass Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer
Completed
2
79
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IMGN853
AbbVie
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
01/24
12/24
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
05/26
05/26
NCT06365853: A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Recruiting
2
100
Europe, Canada, US, RoW
Mirvetuximab Soravtansine, IMGN853, MIRV, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops, Brimonidine tartrate ophthalmic solution eye drops
AbbVie
Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
06/26
06/27
NCT06682988: A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

Recruiting
2
110
US, RoW
Mirvetuximab Soravtansine, MIRV, IMGN853
AbbVie
Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, Fallopian Tube Cancers, High Folate Receptor-Alpha Expression, Platinum Resistant
01/29
02/29
NCT06890338: A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Not yet recruiting
2
140
NA
Carboplatin, Mirvetuximab Soravtansine, MIRV, IMGN853, ELAHERE™, Bevacizumab
AbbVie, GOG Foundation
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
10/29
10/29
NCT05887609: An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Recruiting
2
53
US
Mirvetuximab Soravtansine, IMGN853, MIRV, Olaparib
University of Colorado, Denver, ImmunoGen, Inc.
Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer
04/26
12/27
NCT04606914: Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Recruiting
2
70
US
mirvetuximab soravtansine (MIRV; IMGN853)
University of Alabama at Birmingham
Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer
05/26
05/28
TAK-853-1501, NCT06390995: A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors

Active, not recruiting
1/2
28
Japan
TAK-853, Mirvetuximab Soravtansine
Takeda
Ovarian Cancer, Solid Tumors
04/25
03/27
NCI-2018-00438, NCT03552471: Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Completed
1
25
US
Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, IMGN853, M9346A-sulfo-SPDB-DM4, Pharmacokinetic Study, PHARMACOKINETIC, PK Study, Rucaparib Camsylate, 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt, C0-338, Rubraca, Rucaparib Phosphate
Ohio State University Comprehensive Cancer Center, ImmunoGen, Inc., Clovis Oncology, Inc.
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Uterine Serous Carcinoma, Recurrent Uterine Carcinosarcoma, Platinum Resistant Ovarian Cancer
06/22
12/22
NCI-2016-01913, NCT02996825: Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

Completed
1
44
US
Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Gemcitabine Hydrochloride, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, IMGN853, M9346A-sulfo-SPDB-DM4, Pharmacological Study
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Triple-Negative Breast Carcinoma
02/24
02/24
SL03-OHD-105, NCT05483933: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers

Completed
1
86
Europe, Canada, US
Pegylated Liposomal Doxorubicin + SL-172154, Doxil, PLD, Caelyx, Mirvetuximab + SL-172154, IMGN853, MIRV
Shattuck Labs, Inc.
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma
02/25
02/25
ChiCTR2400088269: A real-world study evaluating the safety and efficacy of Mirvetuximab Soravtansine (MIRV) in platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer with high folate receptor alpha expression

Recruiting
N/A
50
 
None
Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital Hainan Hospital; Hangzhou ZhongMei Huadong Pharmaceutical Co., Ltd., Hangzhou ZhongMei Huadong Pharmaceutical Co., Ltd.
High expression of folate receptor alpha in platinum-resistant advanced high-grade ovarian, primary peritoneal, or fallopian tube cancer
 
 
glembatumumab vedotin (CDX-011) / Celldex
NCT03067935: Individual Patient Expanded Access-Glembatumumab Vedotin

No Longer Available
N/A
NA
glembatumumab vedotin
Celldex Therapeutics
Metastatic gpNMB Expressing Triple Negative Breast Cancer
 
 
anetumab ravtansine (BAY 94-9343) / Bayer
NCI-2018-01503, NCT03587311: Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, not recruiting
2
96
Canada, US
Anetumab Ravtansine, BAY 94-9343, Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
National Cancer Institute (NCI)
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
10/25
10/25
NCT03126630: Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

Active, not recruiting
1/2
49
Canada, US
Anetumab Ravtansine, BAY 94-9343, Laboratory Biomarker Analysis, Pembrolizumab, BCD-201, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, SCH 900475, Pharmacological Study
National Cancer Institute (NCI)
Pleural Malignant Mesothelioma
07/23
09/25
NCI10208, NCT03816358: Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

Active, not recruiting
1
74
Canada, US
Anetumab Ravtansine, BAY 94-9343, Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
01/26
01/26
Ixempra (ixabepilone) / Otsuka, R-Pharm
NCT00977574: Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Active, not recruiting
2
349
US
Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Ixabepilone, (1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione, Azaepothilone B, BMS 247550, BMS-247550, BMS247550, Epothilone, Epothilone-B BMS 247550, Ixempra, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Temsirolimus, CCI 779, CCI-779, CCI-779 Rapamycin Analog, CCI779, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI), NRG Oncology
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Stage IIIA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IIIB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IIIC Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
01/15
03/26
2008-000486-29: A feasibility study of dose-dense FEC wiith G-CSF support followed by dose-dense Ixabepilone wiith G-CSF support as neoadjuvant chemotherapy in ER- negative breast cancer

Ongoing
2
48
Europe
IXEMPRA, IXEMPRA
CONSORZIO ONCOTECH
In ER-negative breast cancer
 
 
NCT03093155: Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab

Completed
2
78
US
Ixabepilone, Ixempra, Bevacizumab, Avastin
Yale University, R-Pharm-US, LLC
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
12/22
12/22
NCT04796324 / 2020-004610-35: Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Suspended
2
60
Europe
Ixabepilone Injection
Allarity Therapeutics, Allarity Therapeutics
Metastatic Breast Cancer
12/24
11/25
NCT00877500: Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

Active, not recruiting
2
116
US
Best Practice, standard of care, standard therapy, Ixabepilone, (1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione, Azaepothilone B, BMS 247550, BMS-247550, BMS247550, Epothilone, Epothilone-B BMS 247550, Ixempra
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Bilateral Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma
12/26
12/26
ORIENTA, NCT06102824: Organoid-based Functional Precision Therapy for Advanced Breast Cancer

Recruiting
2
252
RoW
Organoid-guided treatment, Taxane, Abraxane, Lipusu, Capecitabine, Xeloda, Gemcitabine, Gemzar, Vinorelbine, Navelbine, Eribulin, Halaven, Anthracycline, Doxil, Lipodox, Carboplatin, Paraplatin, Utidelone, UTD1, Trastuzumab deruxtecan, Enhertu, Sacituzumab govitecan, Trodelvy
Guangdong Provincial People's Hospital, First Affiliated Hospital, Sun Yat-Sen University, Sun Yat-sen University, Shantou Central Hospital
HER2-negative Breast Cancer, Advanced Breast Cancer
06/27
06/28
NCT02344147: Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Active, not recruiting
1
30
US
Ixabepilone, BMS 247550, BMS-247550, Temsirolimus, CCI-779, Torisel, Pharmacological Study, pharmacological studies
Mayo Clinic, National Cancer Institute (NCI)
Adult Solid Neoplasm
06/16
 
NCT01375829: Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Active, not recruiting
1
22
US
Ixabepilone, (1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione, Azaepothilone B, BMS 247550, BMS-247550, BMS247550, Epothilone, Epothilone-B BMS 247550, Ixempra, Pharmacological Study, Temsirolimus, CCI 779, CCI-779, CCI-779 Rapamycin Analog, CCI779, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI)
Adult Solid Neoplasm
06/18
03/26
NCT03393741: Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

Terminated
N/A
5
US
Taxane, paclitaxel, nab-paclitaxel, docetaxel, Vinorelbine, vinca alkaloid, Ixabepilone, epothilone, Eribulin, halichondrins, Chemotherapy
University of Wisconsin, Madison, National Cancer Institute (NCI)
Breast Cancer, Breast Neoplasms
02/24
02/24
Halaven (eribulin mesylate) / Eisai
2020-001938-35: AIRE: Investigation of the immune response after chemotherapy treatment with Eribulin: A trial for female patients with advanced breast cancer. AIRE: Untersuchung der Immunantwort nach Behandlung mit der Chemotherapie Eribulin: Eine Studie für Patientinnen mit fortgeschrittenem Brustkrebs.

Not yet recruiting
4
84
Europe
Eribulin, Paclitaxel, Paclitaxel Albumin-Bound, Capecitabine, Vinorelbine, Solution for injection, Concentrate for solution for infusion, Powder for solution for infusion, Tablet, Halaven, Paclitaxel, nab-Paclitaxel, Capecitabine, Vinorelbine
Institut für Frauengesundheit GmbH, Institut für Frauengesundheit (IFG) GmbH
Female patients diagnosed with HER2 negative advanced breast cancer, which had received at least one previous chemotherapy Patientinnen, die mit einem HER2 negativen Brustkrebs im fortgeschrittenem Stadium diagnostiziert wurden und zuvor mindestens eine Chemotherapie erhielten., Female patients which were diagnosed with advanced breast cancer. The tumor should not have a certain marker (HER2) on its surface (HER2 negative breast cancer). Patientinnen, die mit einem Brustkrebs im fortgeschrittenem Stadium diagnostiziert wurden. Den Tumorzellen fehlt ein bestimmter Marker (HER2) auf der Oberfläche (HER2-negativer Brustkrebs)., Diseases [C] - Cancer [C04]
 
 
EPIC, ChiCTR2000038832: A multicenter, exploratory study of Eribulin combined with Pyrotinib in patients with advanced HER2-positive breast cancer who have previously used Taxanes and are resistant to Herceptin

Recruiting
4
50
 
Eribulin combine Pyrotinib
The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University, Self-funded
Breast cancer
 
 
ChiCTR2100048468: A real-world study of the efficacy and safety of Eribulin in different subtypes of advanced breast cancer

Recruiting
4
150
 
Eribulin
Shandong Cancer Hospital; Shandong Cancer Hospital, self-raised
breast cancer
 
 
ChiCTR2100051610: Single-center clinical study of the effectiveness and completeness of eribulin in combination with small molecule complexine kinase inhibitors for advanced solid tumors

Not yet recruiting
4
40
 
Chemotherapy + Targeted
Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, Wu Jieping Medical Foundation (Clinical Research Special Grant Fund)
Tumor patients
 
 
AIRE, NCT05033769: Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer

Recruiting
4
82
Europe
Eribulin Injection [Halaven], Eribulin, Paclitaxel injection, Paclitaxel
Institut fuer Frauengesundheit, Eisai GmbH
Breast Cancer Female, Neoplasm, Breast, Breast Cancer Metastatic
07/23
09/23
ChiCTR2100052828: Multicenter, randomized study of eribulin plus capecitabine versus capecitabine in HER2-negative patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes

Recruiting
4
320
 
Eribulin mesilate 1.4 mg/m^2 intravenously over 2-5 minutes on days 1 and 8 of every 21-day cycle, in combine with Capecitabine tablet 1000 mg/m^2 orally bid for days 1 to 14 of every 21-day cycle ;Capecitabine tablet 1250 mg/m^2 orally bid for days 1 to 14 of every 21-day cycle
Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences, Eisai China lnc.
Breast cancer
 
 
ChiCTR2300078142: Fruquintinib combined with eribulin as 2nd line or above treatment in patients with HR positive HER-2 negative breast cancer

Recruiting
4
40
 
fruquintinib; Eribulin
Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, Self-funded
Breast Cnacer
 
 
ChiCTR2500102304: The effect of prolonged analgesia with Eribulin on postoperative pain and knee function in patients undergoing total knee arthroplasty: a prospective randomized controlled study.

Not yet recruiting
4
80
 
Oral administration of Erichoxib (100mg per dose, twice a day) 1 day before surgery, followed by 100mg of Erichoxib 2 hours after surgery, then 100mg of Erichoxib every 12 hours.; Oral placebo (100mg per dose, 2 doses per day) 1 day before surgery, followed by 100mg of Eribulin 2 hours after surgery, and then 100mg of Eribulin every 12 hours.
Xi'an Honghui hospital; Xi'an Honghui hospital, Self-raised
Osteoarthritis of knee joint
 
 
ACTRN12607000176460: A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 versus Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes

Recruiting
3
1100
 
Eisai, Eisai
Breast Cancer Locally Advanced or Metastatic
 
 
ACTRN12612000100897: Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

Active, not recruiting
3
540
 
Eisai Limited, Eisai Limited
Non-small cell lung cancer
 
 
OlympiAD, NCT02000622 / 2013-005137-20: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Checkmark Approved for HER2 - locally-advanced or metastatic breast cancer with gBRCAm
Apr 2019 - Apr 2019: Approved for HER2 - locally-advanced or metastatic breast cancer with gBRCAm
Checkmark Approval
Jan 2019 - Apr 2019: Approval
Checkmark Approved for unresectable/recurrent BRCA-mutated, HER2-ve breast cancer (based on OlympiAD trial)
More
Active, not recruiting
3
302
Europe, Japan, US, RoW
Olaparib, Physician's choice chemotherapy
AstraZeneca, Myriad Genetic Laboratories, Inc., Merck Sharp & Dohme LLC
Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
12/16
12/25
TULIP, NCT03262935 / 2017-001994-18: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Completed
3
437
Europe, Canada, US, RoW
(vic-)trastuzumab duocarmazine, SYD985, Trastuzumab vc-seco-DUBA, Physician's choice, Lapatinib (Lap), Capecitabine (Cap), Trastuzumab (T), Vinorelbine (Vino), Eribulin (Eri)
Byondis B.V.
Metastatic Breast Cancer
03/21
06/22
2018-004211-42: A clinical study to compare treatment of Balixafortide in combination with Eribulin or Eribulin alone, in patients with no protein HER2 present in their cells and had locally repeated or spread breast cancer.

Not yet recruiting
3
384
RoW, Europe
Balixafortide, Halaven, POL6326, Concentrate for solution for infusion, Solution for injection, Halaven
Polyphor Ltd., Polyphor Ltd.
Patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer, Patients with breast cells that do not have on their surface the HER2 protein (receptor for the Human epidermal growth factor receptor 2) and that have locally repeated or spread breast cancer, Diseases [C] - Cancer [C04]
 
 
FORTRESS, NCT03786094: Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

Terminated
3
432
Europe, US, RoW
Eribulin, Eribulin Injection [Halaven], Balixafortide, POL6326
Spexis AG
Metastatic Breast Cancer, Locally Recurrent Breast Cancer
10/21
10/21
2020-005620-12: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Cancer Ensayo clínico de Dato-DXd en comparación con la quimioterapia de elección del investigador en cáncer de mama inoperable o metastásico, con receptores hormonales positivos HER2 negativo.

Not yet recruiting
3
700
Europe
Datopotamab deruxtecan, Eribulin mesylate, Capecitabine, Gemcitabine, Vinorelbine, DS-1062a, Powder for concentrate for solution for infusion, Solution for injection/infusion, Film-coated tablet, Powder for solution for infusion, HALAVEN, Capecitabine Accord, Bendacitabin, Bendarelbin
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy Cáncer de mama inoperable o metastásico, con receptores hormonales positivos, HER2 negativo, tratado una o dos líneas previas de quimioterapia sistémica, Breast Cancer Cáncer de mama, Diseases [C] - Cancer [C04]
 
 
DESTINY-Breast04, NCT03734029 / 2018-003069-33: Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed []

Jan 2023 - Jun 2023: Regulatory decision in China for 3L HER2-low breast cancer (based on DESTINY-Breast04 trial)
Jan 2023 - Mar 2023: Regulatory decision in Japan for 3L HER2-low breast cancer (based on DESTINY-Breast04 trial)
Checkmark Approved in EU as monotherapy for HER2 low breast cancer based on DESTINY-Breast04 trial
Jan 2023 - Jan 2023: Approved in EU as monotherapy for HER2 low breast cancer based on DESTINY-Breast04 trial
Checkmark Approved in Canada for the treatment of 2L HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer
More
Active, not recruiting
3
557
Europe, Canada, Japan, US, RoW
Trastuzumab deruxtecan (DS-8201a), DS-8201a, Capecitabine, Eribulin, Gemcitabine, Paclitaxel, Nab-paclitaxel
Daiichi Sankyo, Daiichi Sankyo Co., Ltd., AstraZeneca
Breast Cancer
01/22
10/25
EMERALD, NCT03264547: A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Recruiting
3
480
Japan
Pertuzumab, Perjeta, Trastuzumab, Herceptin, Docetaxel, Taxotere, Paclitaxel, Taxol, Eribulin, Halaven
Japan Breast Cancer Research Group, Eisai Co., Ltd.
Breast Cancer
04/22
10/23
EVER-132-002, NCT04639986: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Active, not recruiting
3
331
RoW
Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, GS-0132, Eribulin Mesylate Injection, Halaven, Capecitabine Oral Product, Xeloda, Gemcitabine Injection, Gemzar, Vinorelbine injection, Navelbine
Gilead Sciences, Iqvia Pty Ltd, Medidata Solutions, Parexel
Metastatic Breast Cancer
12/25
12/25
NCT05134194: A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer

Terminated
3
1
RoW
Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine, Capecitabine/eribulin/gemcitabine/vinorelbine
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Triple Negative Breast Cancer
01/22
12/22
NCT06857305: Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial

Enrolling by invitation
3
192
RoW
Eribulin biweekly regimen, Eribulin standard regimen
Ma Fei，MD
Breast Cancer Metastatic
07/26
07/26
NCT06143553: Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

Recruiting
3
168
RoW
Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate injection, Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection, Paclitaxel (albumin-bound)
Shanghai Yizhong Pharmaceutical Co., Ltd.
Metastatic Breast Cancer (MBC)
12/25
12/25
NCT05346861: Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Recruiting
3
240
RoW
Trastuzumab plus chemotherapy, Trastuzumab in combination with pyrotinib plus chemotherapy
Fudan University
HER2-positive Breast Cancer, Metastatic Breast Cancer
10/23
10/24
OptiTROP-Breast01, NCT05347134: SKB264 Injection Vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Active, not recruiting
3
254
RoW
SKB264, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Triple Negative Breast Cancer
11/23
03/25
B2023-686-01, NCT06268652: Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer

Recruiting
3
302
RoW
Organoid-guided personalized treatment, OGPT, Gemcitabine, Gemzar, Capecitabine, Xeloda, Vinorelbine, Navelbine, Eribulin, Halaven
Sun Yat-sen University
Breast Cancer, Refractory Breast Carcinoma
02/26
01/28
SYSKY-2023-1016-01, NCT06255392: Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Not yet recruiting
3
200
RoW
Fluzoparib, Apatinib Mesylate, Capecitabine tablets, Vinorelbine Tartrate Oral, Eribulin mesylate injection, Gemcitabine Hydrochloride, Paclitaxel-albumin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
03/31
03/31
RESQ, jRCTs011180026: A Phase III, Open Label, Randomized, Controlled, Multicenter Study, comparing Eribulin with S1, to assess Health-related Quality of Life (HRQoL) in the Treatment of Her2 negative Metastatic Breast Cancer Patients

Completed
3
330
Japan
Halaven (eribulin mesylate) - Eisai, Teysuno (gimeracil/oteracil/tegafur) - Nordic Group, Otsuka
CSPOR-BC, Eisai Co. Ltd.
metastatic breast cancer
 
 
SKB264-Ⅲ-11, NCT06279364: A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Recruiting
3
524
RoW
SKB264, Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, Carboplatin
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Triple Negative Breast Cancer
07/26
07/26
NCT06343948: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer

Active, not recruiting
3
383
RoW
BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, Eribulin, Vinorelbine, Gemcitabine, Capecitabine
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
HR+HER2- Breast Cancer
05/26
05/26
NCT06382142: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Recruiting
3
406
RoW
BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, Eribulin, Vinorelbine, Gemcitabine, Capecitabine
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Triple-Negative Breast Cancer
06/26
06/26
INVINCIBLE-3, NCT06263231: A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas

Recruiting
3
333
Europe, Canada, US
INT230-6, Eribulin, Trabectedin, Pazopanib
Intensity Therapeutics, Inc., Premier Research Group plc
Sarcoma,Soft Tissue
12/27
12/28
NCT06383767: A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Recruiting
3
378
RoW
ESG401, Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)
Qilu Pharmaceutical Co., Ltd.
Metastatic Breast Cancer
06/27
07/28
NCT06519370: FDA018-ADC Vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Recruiting
3
350
RoW
FDA018-ADC, FDA018-Antibody-drug Conjugate, Eribulin, Halaven, Capecitabine, Xeloda, Gemcitabine, Gemzar, Vinorelbine, Navelbine
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Triple Negative Breast Cancer
08/26
06/27
EmpowHER-303, NCT06435429: A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Recruiting
3
550
Europe, Canada, Japan, US, RoW
Zanidatamab, Trastuzumab, Eribulin, Vinorelbine, Gemcitabine, Capecitabine
Jazz Pharmaceuticals
Metastatic HER2-positive Breast Cancer
09/28
11/31
DETECT V, NCT02344472 / 2014-002249-22: Detect V / CHEVENDO (Chemo vs. Endo)

Active, not recruiting
3
271
Europe
pertuzumab, Perjeta®, Trastuzumab, Herceptin®, Capecitabine, Paclitaxel, Vinorelbine, Docetaxel, Exemestane, Letrozole, Anastrozole, Fulvestrant, Ribociclib, Kisqali®, nab-Paclitaxel, eribulin, leuprorelin, goserelin
Prof. Wolfgang Janni, Roche Pharma AG, Novartis Pharmaceuticals, Eisai GmbH, Celgene Corporation
Metastatic Breast Cancer
01/25
01/25
TROPiCS-02, NCT03901339 / 2018-004201-33: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Jul 2023 - Dec 2023: Regulatory decision in EU for HR+/HER2 breast cancer
Checkmark Approved for unresectable, locally advanced or metastatic HR+, HER2-ve metastatic breast cancer based on data from TROPiCS-02 study
Feb 2023 - Feb 2023: Approved for unresectable, locally advanced or metastatic HR+, HER2-ve metastatic breast cancer based on data from TROPiCS-02 study
Checkmark EMA validated MAA for Trodelvy for pre-treated HR+/HER2- metastatic breast cancer
Jan 2023 - Jan 2023: EMA validated MAA for Trodelvy for pre-treated HR+/HER2- metastatic breast cancer
More
Completed
3
543
Europe, Canada, US
Sacituzumab Govitecan-hziy, IMMU-132, GS-0132, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Gilead Sciences
Metastatic Breast Cancer
10/23
10/23
ANGLeD, NCT03613181: ANG1005 in Leptomeningeal Disease From Breast Cancer

Not yet recruiting
3
150
NA
ANG1005, paclitaxel trevatide, Physician's Best Choice, capecitabine, eribulin, high-dose IV methotrexate.
Angiochem Inc
Leptomeningeal Carcinomatosis, Leptomeningeal Metastases, Brain Metastases, HER2-negative Breast Cancer
12/24
12/24
BCTOP-T-M02, NCT05760378: Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Recruiting
3
223
RoW
Famitinib, Camrelizumab, nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin
Fudan University
Triple-Negative Breast Cancer
01/25
01/27
SHR-A1811-III-306, NCT05814354: SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial

Recruiting
3
530
RoW
SHR-A1811, Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel
Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer
01/25
06/26
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Not yet recruiting
3
400
RoW
JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Breast Cancer
04/25
03/29
NCT06889688: Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer

Active, not recruiting
3
246
RoW
Camrelizumab+Apatinib+Eribulin, Physician's choice chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer Stage IV
09/30
03/31
NCT06957886: A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

Recruiting
3
564
RoW
BL-M07D1, Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
HER2-low Breast Cancer
05/27
12/27
BRIA-ABC, NCT06072612: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting
3
404
US
SV-BR-1-GM, Part of the Bria-IMT regimen, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
BriaCell Therapeutics Corporation
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
01/26
06/26
TQB2930-III-01, NCT07047365: TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Not yet recruiting
3
416
RoW
TQB2930+ chemotherapy, Trastuzumab+ chemotherapy
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
HER2-positive Advanced Breast Cancer
06/28
12/28
BCTOP-T-M03, NCT05954442: Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

Recruiting
3
203
RoW
Everolimus, Afinitor, Investigator's Choice of Chemotherapy, ICC
Fudan University
Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation
08/25
08/26
TROPION-Breast01, NCT05104866 / 2020-005620-12: A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy

Jan 2024 - Dec 2024: Data from TROPION-Breast01 trial for inoperable or metastatic HR+, HER2- breast cancer
Hourglass Feb 2024 - Mar 2024 : Q4 FY'23 - Acceptance of regulatory submission in US for 2-3L HR+, HER2- breast cancer (based on TROPION-Breast01 trial)
Active, not recruiting
3
732
Europe, Canada, Japan, US, RoW
Dato-DXd, Datopotamab deruxtecan (Dato-DXd, DS-1062a), Capecitabine, Gemcitabine, Eribulin, Eribulin Mesylate, Vinorelbine
AstraZeneca, Daiichi Sankyo
Breast Cancer
07/24
12/25
BCTOP-T-M01, NCT05806060: Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer

Recruiting
3
192
RoW
VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine, Bevacizumab (BP102), nab-paclitaxel, with maintenance of capecitabine, Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1, VEGFR and TPC
Fudan University
Triple-Negative Breast Cancer
08/25
02/26
NCT06732323: A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Not yet recruiting
3
504
RoW
ESG401, Investigator's Choice Chemotherapy
Qilu Pharmaceutical Co., Ltd.
Triple-Negative Breast Cancer (TNBC)
06/27
07/28
TROPION-Breast02, NCT05374512 / 2021-005223-21: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy

Hourglass May 2025 - Jun 2025 : Initial data for 1L PD-1/PD-L1 ineligible TNBC
Jan 2024 - Dec 2024: Acceptance of regulatory submission for 1L TNBC (based TROPION-Breast02 trial)
Active, not recruiting
3
644
Europe, Canada, Japan, US, RoW
Dato-DXd, Datopotamab deruxtecan (Dato-DXd, DS-1062a), Paclitaxel, Nab-paclitaxel, Carboplatin, Capecitabine, Eribulin mesylate
AstraZeneca, Daiichi Sankyo
Breast Cancer
12/25
12/25
SKB264-Ⅲ-10, NCT06081959: Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

Recruiting
3
376
RoW
SKB264, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Metastatic Breast Cancer
03/26
12/27
ALPHABET, NCT05063786 / 2020-005639-65: Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer

Active, not recruiting
3
27
Europe
Trastuzumab, Herceptin, Alpelisib, Piqray, Fulvestrant, Faslodex, Vinorelbine, Navelbine, Capecitabine, Xeloda, Eribulin, Halaven
Spanish Breast Cancer Research Group, ETOP IBCSG Partners Foundation, Breast International Group, Novartis Pharmaceuticals
Advanced Breast Cancer
06/25
06/25
SWOG S1937, NCT04579224: Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Recruiting
3
184
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Eribulin Mesylate, B1939 Mesylate, E7389, ER-086526 Mesylate, Halaven, Halichondrin B Analog, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU 132, IMMU-132, IMMU132, RS7 SN38, RS7-SN38, RS7SN38, Sacituzumab Govitecan-hziy, Trodelvy
National Cancer Institute (NCI)
Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
08/30
08/30
2ND-STEP, jRCTs031190152: JCOG1802: A randomized phase II trial of 2nd line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib

Active, not recruiting
2
120
Japan
Yondelis (trabectedin) - Otsuka, PharmaMar, Valeo Pharma, J&J, Halaven (eribulin mesylate) - Eisai, Votrient (pazopanib) - Novartis, BeiGene
Oita University Hospital, National Cancer Center Japan,Japan Agency for Medical Research and Development
Advanced soft tissue sarcoma
 
 
2012-003505-10: Gemcitabine and Eribulin as first line treatment of advanced triple-negative breast cancer. Gemcitabina ed Eribulina come trattamento di prima linea nel carcinoma mammario triplo-negativo in fase avanzata.

Ongoing
2
83
Europe
GEMCITABINA HOS.IT*INF FL 1G, HALAVEN*EV 6FL 2ML 0,44MG/ML, GEMCITABINA HOS.IT*INF FL 1G, HALAVEN*EV 6FL 2ML 0,44MG/ML
GRUPPO ONCOLOGICO ITALIANO DI RICERCA, EISAI Srl
Locally recurrent or metastatic triple negative breast cancer. Pazienti con tumore della mammella triplo negativo con recidiva locale o metastatico.
 
 
2017-003621-15: A Phase II study of a Combination of Eribulin and capecitabiNe in second line Treatment after the failure of gemcitabine/abraxane first line in advanced pancreatic cancer Studio di Fase II di eribulina in combinazione con capecitabina per il trattamento di seconda linea in pazienti affetti da carcinoma pancreatico avanzato dopo fallimento di terapia di prima linea con gemcitabina/abraxane.

Not yet recruiting
2
25
Europe
HALAVEN, Capecitabina accord 150, Capecitabina Accord 500, [-], Solution for infusion, Film-coated tablet, HALAVEN - 0.44MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 2ML 6 FLACONCINI, CAPECITABINA ACCORD - 150 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PVDC/ALU) - 120 COMPRESSE, CAPECITABINA ACCORD - 500 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PVDC/ALU) - 120 COMPRESSE
AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA, EISAI srl
advanced pancreatic cancer tumore del pancreas avanzato, advanced pancreatic cancer tumore del pancreas avanzato, Diseases [C] - Cancer [C04]
 
 
2017-004652-35: Second line ERIbulin followed by CApecitabine or the reverse sequence in HER2-negative Metastatic Breast Cancer (MBC) patients: a randomized phase II study – ERICA trial ERIbulina in seconda linea seguita da CApecitabina o sequenza inversa in pazienti con carcinoma mammario metastatico (MBC) HER2-negativo: uno studio randomizzato di fase II – Studio ERICA

Ongoing
2
150
Europe
HALAVEN, Xeloda, [Eribulina], [Capecitabina], Solution for injection, Film-coated tablet, HALAVEN - 0.44MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 2ML 6 FLACONCINI, XELODA - 500 MG 120 COMPRESSE FILMRIVESTITE IN BLISTER USO ORALE
CONSORZIO ONCOTECH, EISAI S.r.l.
HER2-negative Metastatic Breast Cancer Carcinoma mammario metastatico HER2-negativo, Metastatic Breast Tumour Tumore al seno metastatico, Diseases [C] - Cancer [C04]
 
 
NCT03051659: A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer

Checkmark In combination with eribulin in HR+ve, HER2-ve mBC
Sep 2020 - Sep 2020: In combination with eribulin in HR+ve, HER2-ve mBC
Completed
2
90
US
Eribulin Mesylate, Halaven, Pembrolizumab, Keytruda
Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC
Breast Cancer
10/18
09/23
2018-004571-12: Trial in advanced Solitary Fibrous Tumor (SFT) Studio clinico nel Tumore Fibroso Solitario (TFS)

Not yet recruiting
2
20
Europe
Eribulina, [30058], Solution for injection, HALAVEN - 0.44MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 2ML 6 FLACONCINI
ITALIAN SARCOMA GROUP, Eisai Italy
Advanced Solitary Fibrous Tumor (SFT) Tumore Fibroso Solitario in fase avanzata, Advanced Solitary Fibrous Tumor (SFT) Tumore Fibroso Solitario in fase avanzata, Diseases [C] - Cancer [C04]
 
 
2020-004909-32: Can treatment with Eribulin chemotherapy restore the sentivity in cancertissue in subsequent treatment with antihormon treatment? A study for patients with ER positive, HER2 normal breast cancer. Kan behandling med kemoterapien eribulin genskabe kræftvævets følsomhed for efterfølgende antihormonbehandling. Et studie til patienter med ER positiv, HER2 normal brystkræft.

Not yet recruiting
2
42
Europe
Halaven, Concentrate and solvent for solution for infusion, Tablet, Halaven, Aromasin
Department of Oncology, Department of oncology, University Hospital of Aarhus, Skejby
Metastatic breast cancer with estrogene positive and HER2 normal/negative subtype. Metastatisk brystkræft med østrogenreceptor positive og HER2 normal/negative HER2 receptor status., Breast cancer with has spred to other organs with is sentitive to estrogen and has a normal HER2 receptor status. Brystkræft med spredning til andre organer som er østrogen receptor positive og har HER2 normal udtryk ved immunhistokemi., Diseases [C] - Cancer [C04]
 
 
2017-004324-30: Clinical Trial to study the effect of the treatment with eribulin and endocrine therapy in metastatic breast cancer patients Ensayo clínico para estudiar el efecto de tratamiento con eribulina y terapia endocrina en pacientes con cáncer de mama avanzado

Not yet recruiting
2
60
Europe
Solution for injection, HALAVEN
Medica Scientia Innovation Research (MEDSIR), EISAI FARMACEUTICA S.A.
Luminal Metastatic Breast Cancer Cáncer de mama metastásico luminal, Metastatic Breast Cancer Cáncer de mama metastásico, Diseases [C] - Cancer [C04]
 
 
NCT02623972: A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Active, not recruiting
2
22
US
Eribulin, Halaven, B1939 mesylate, Adriamycin, Doxorubicin, Cyclophosphamide, Cytoxan®, Neosar®
Dana-Farber Cancer Institute, Eisai Inc.
Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
05/21
12/26
NCT04624711: Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

Recruiting
2
40
RoW
Eribulin Mesylate, Halaven, Anlotinib hydrochloride, Anlotinib
The First Affiliated Hospital with Nanjing Medical University
HER2-negative Breast Cancer
06/22
12/22
TEMPLATE, NCT04913571: Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study

Not yet recruiting
2
265
RoW
Eribulin, Tislelizumab
Fudan University
Triple Negative Breast Cancer
06/22
06/23
NCT03331250: Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

Active, not recruiting
2
13
US
Eribulin, Halaven
Massachusetts General Hospital, Eisai Inc.
Angiosarcoma, Epithelioid Hemangioendothelioma
07/23
05/25
NCT04517292: Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)

Not yet recruiting
2
160
RoW
Eribulin,cisplatin, Gemcitabine,cisplatin
Fudan University
Breast Cancer
07/22
10/22
Immuno2020-01, NCT04303741: A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

Active, not recruiting
2
46
RoW
Camrelizumab, Apatinib, Eribulin, Eribulin Mesylate
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
11/22
08/23
SAFIR02_Breast, NCT02299999 / 2013-001652-36: - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Active, not recruiting
2
1460
Europe
AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, ARRY-142866, Vandetanib, CAPRELSA, Bicalutamide, Casodex, Olaparib, Lynparza, Anthracyclines, Doxorubicin, Epirubicin, liposomal doxorubicin, Taxanes, paclitaxel, docetaxel, cyclophosphamide, Novatrex, Imeth, DNA intercalators, capecitabine, 5-FU, gemcitabine, Methotrexate, vinca alkaloids, vinorelbine, vinblastine, vincristine, Platinum based chemotherapies, Platinum, carboplatin, cisplatin, Bevacizumab, Avastin, Mitomycin C, Ametycine, Eribulin, Halaven, MEDI4736
UNICANCER, Fondation ARC, AstraZeneca
Metastatic Breast Cancer
12/22
12/25
NCT05546255: Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Recruiting
2
40
RoW
Eribulin Mesylate, Lobaplatin
Chinese Academy of Medical Sciences
Triple Negative Breast Cancer
12/22
12/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Elahere (mirvetuximab soravtansine-gynx) / AbbVie
NCT05622890: A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer

Recruiting
3
35
RoW
Mirvetuximab Soravtansine, IMGN853, MIRV
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
04/23
12/23
MIRASOL, NCT04209855 / 2019-003509-80: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
Jan 2023 - Dec 2023: Market entry in ex-US for platinum-resistant ovarian cancer
Hourglass Jan 2023 - Mar 2023 : Top-line data from MIRASOL trial for high-grade epithelial ovarian cancer
Hourglass Jul 2022 - Sep 2022 : Approval for high-grade epithelial ovarian cancer (based on MIRASOL trial)
Completed
3
453
Europe, Canada, US, RoW
Mirvetuximab Soravtansine, MIRV, IMGN853, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
AbbVie, Gynecologic Oncology Group, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/23
08/24
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
520
Europe, Canada, Japan, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
04/29
04/29
2018-004207-39: Mirvetuximab Soravtansine in patients with high expression of folate receptor alpha in their tumor and recurrent ovarian cancer

Not yet recruiting
2
136
Europe
Mirvetuximab Soravtansine, Powder and solvent for concentrate for solution for infusion, Solution for infusion, Capsule, hard, Film-coated tablet, , Caelyx, Carboplatin Kabi, Paclitaxel-GRY®, Gemedac®, Zejula, Lynparza, Rubraca
AGO Research GmbH, ImmunoGen, Inc.
This trial evaluates the efficacy and safety of Mirvetuximab soravtansine (IMGN853) plus Carboplatin chemotherapy in FRα high patients with recurrent ovarian cancer who are eligible for platinum-based chemotherapy., Safety and efficacy for carboplatin with Mirvetuximab soravtansine (IMGN853) compared to carboplatin combination chemotherapy, Diseases [C] - Cancer [C04]
 
 
2021-003592-34: c Un estudio para probar mirvetuximab soravtansina en mujeres con cánceres epiteliales de ovario, peritoneales primarios o de trompa de Falopio sensibles al platino.

Not yet recruiting
2
75
Europe
mirvetuximab soravtansine, IMGN853, Concentrate for solution for injection/infusion, Pred Forte
ImmunoGen, Inc., IMMUNOGEN, INC., ImmunoGen, Inc.
Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression Cánceres epiteliales de ovario, peritoneales primarios o de trompa de Falopio recurrentes, sensibles al platino y con alta expresión del receptor de folatos alfa, Cancer of ovary and related organs Cáncer de ovario y órganos afines, Diseases [C] - Cancer [C04]
 
 
NCT03835819: A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

Active, not recruiting
2
18
US
Pembrolizumab, Keytruda, IMGN853, Mirvetuximab soravtansine, Elahere
Dana-Farber Cancer Institute, ImmunoGen, Inc., Merck Sharp & Dohme LLC
Endometrial Cancer
06/24
05/27
NCT03832361: Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

Recruiting
2
50
US
IMGN853, mirvetuximab soravtansine
Alessandro Santin, ImmunoGen, Inc.
Endometrial Cancer
10/25
10/28
MIROVA, NCT04274426 / 2018-004207-39: Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Active, not recruiting
2
136
Europe
Carboplatin, Pegylated liposomal doxorubicin (PLD), Gemcitabine, Paclitaxel, Mirvetuximab Soravtansine
AGO Research GmbH, ImmunoGen, Inc.
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
12/25
12/26
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
Hourglass Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
Hourglass Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
Hourglass Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer
Completed
2
79
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IMGN853
AbbVie
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
01/24
12/24
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
05/26
05/26
NCT06365853: A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Recruiting
2
100
Europe, Canada, US, RoW
Mirvetuximab Soravtansine, IMGN853, MIRV, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops, Brimonidine tartrate ophthalmic solution eye drops
AbbVie
Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
06/26
06/27
NCT06682988: A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

Recruiting
2
110
US, RoW
Mirvetuximab Soravtansine, MIRV, IMGN853
AbbVie
Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, Fallopian Tube Cancers, High Folate Receptor-Alpha Expression, Platinum Resistant
01/29
02/29
NCT06890338: A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Not yet recruiting
2
140
NA
Carboplatin, Mirvetuximab Soravtansine, MIRV, IMGN853, ELAHERE™, Bevacizumab
AbbVie, GOG Foundation
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
10/29
10/29
NCT05887609: An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Recruiting
2
53
US
Mirvetuximab Soravtansine, IMGN853, MIRV, Olaparib
University of Colorado, Denver, ImmunoGen, Inc.
Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer
04/26
12/27
NCT04606914: Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Recruiting
2
70
US
mirvetuximab soravtansine (MIRV; IMGN853)
University of Alabama at Birmingham
Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer
05/26
05/28
TAK-853-1501, NCT06390995: A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors

Active, not recruiting
1/2
28
Japan
TAK-853, Mirvetuximab Soravtansine
Takeda
Ovarian Cancer, Solid Tumors
04/25
03/27
NCI-2018-00438, NCT03552471: Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Completed
1
25
US
Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, IMGN853, M9346A-sulfo-SPDB-DM4, Pharmacokinetic Study, PHARMACOKINETIC, PK Study, Rucaparib Camsylate, 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt, C0-338, Rubraca, Rucaparib Phosphate
Ohio State University Comprehensive Cancer Center, ImmunoGen, Inc., Clovis Oncology, Inc.
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Uterine Serous Carcinoma, Recurrent Uterine Carcinosarcoma, Platinum Resistant Ovarian Cancer
06/22
12/22
NCI-2016-01913, NCT02996825: Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

Completed
1
44
US
Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Gemcitabine Hydrochloride, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, IMGN853, M9346A-sulfo-SPDB-DM4, Pharmacological Study
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Triple-Negative Breast Carcinoma
02/24
02/24
SL03-OHD-105, NCT05483933: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers

Completed
1
86
Europe, Canada, US
Pegylated Liposomal Doxorubicin + SL-172154, Doxil, PLD, Caelyx, Mirvetuximab + SL-172154, IMGN853, MIRV
Shattuck Labs, Inc.
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma
02/25
02/25
ChiCTR2400088269: A real-world study evaluating the safety and efficacy of Mirvetuximab Soravtansine (MIRV) in platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer with high folate receptor alpha expression

Recruiting
N/A
50
 
None
Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital Hainan Hospital; Hangzhou ZhongMei Huadong Pharmaceutical Co., Ltd., Hangzhou ZhongMei Huadong Pharmaceutical Co., Ltd.
High expression of folate receptor alpha in platinum-resistant advanced high-grade ovarian, primary peritoneal, or fallopian tube cancer
 
 
glembatumumab vedotin (CDX-011) / Celldex
NCT03067935: Individual Patient Expanded Access-Glembatumumab Vedotin

No Longer Available
N/A
NA
glembatumumab vedotin
Celldex Therapeutics
Metastatic gpNMB Expressing Triple Negative Breast Cancer
 
 
anetumab ravtansine (BAY 94-9343) / Bayer
NCI-2018-01503, NCT03587311: Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, not recruiting
2
96
Canada, US
Anetumab Ravtansine, BAY 94-9343, Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
National Cancer Institute (NCI)
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
10/25
10/25
NCT03126630: Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

Active, not recruiting
1/2
49
Canada, US
Anetumab Ravtansine, BAY 94-9343, Laboratory Biomarker Analysis, Pembrolizumab, BCD-201, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, SCH 900475, Pharmacological Study
National Cancer Institute (NCI)
Pleural Malignant Mesothelioma
07/23
09/25
NCI10208, NCT03816358: Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

Active, not recruiting
1
74
Canada, US
Anetumab Ravtansine, BAY 94-9343, Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
01/26
01/26
Ixempra (ixabepilone) / Otsuka, R-Pharm
NCT00977574: Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Active, not recruiting
2
349
US
Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Ixabepilone, (1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione, Azaepothilone B, BMS 247550, BMS-247550, BMS247550, Epothilone, Epothilone-B BMS 247550, Ixempra, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Temsirolimus, CCI 779, CCI-779, CCI-779 Rapamycin Analog, CCI779, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI), NRG Oncology
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Stage IIIA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IIIB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IIIC Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage, Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
01/15
03/26
2008-000486-29: A feasibility study of dose-dense FEC wiith G-CSF support followed by dose-dense Ixabepilone wiith G-CSF support as neoadjuvant chemotherapy in ER- negative breast cancer

Ongoing
2
48
Europe
IXEMPRA, IXEMPRA
CONSORZIO ONCOTECH
In ER-negative breast cancer
 
 
NCT03093155: Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab

Completed
2
78
US
Ixabepilone, Ixempra, Bevacizumab, Avastin
Yale University, R-Pharm-US, LLC
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
12/22
12/22
NCT04796324 / 2020-004610-35: Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Suspended
2
60
Europe
Ixabepilone Injection
Allarity Therapeutics, Allarity Therapeutics
Metastatic Breast Cancer
12/24
11/25
NCT00877500: Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

Active, not recruiting
2
116
US
Best Practice, standard of care, standard therapy, Ixabepilone, (1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione, Azaepothilone B, BMS 247550, BMS-247550, BMS247550, Epothilone, Epothilone-B BMS 247550, Ixempra
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Bilateral Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma
12/26
12/26
ORIENTA, NCT06102824: Organoid-based Functional Precision Therapy for Advanced Breast Cancer

Recruiting
2
252
RoW
Organoid-guided treatment, Taxane, Abraxane, Lipusu, Capecitabine, Xeloda, Gemcitabine, Gemzar, Vinorelbine, Navelbine, Eribulin, Halaven, Anthracycline, Doxil, Lipodox, Carboplatin, Paraplatin, Utidelone, UTD1, Trastuzumab deruxtecan, Enhertu, Sacituzumab govitecan, Trodelvy
Guangdong Provincial People's Hospital, First Affiliated Hospital, Sun Yat-Sen University, Sun Yat-sen University, Shantou Central Hospital
HER2-negative Breast Cancer, Advanced Breast Cancer
06/27
06/28
NCT02344147: Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Active, not recruiting
1
30
US
Ixabepilone, BMS 247550, BMS-247550, Temsirolimus, CCI-779, Torisel, Pharmacological Study, pharmacological studies
Mayo Clinic, National Cancer Institute (NCI)
Adult Solid Neoplasm
06/16
 
NCT01375829: Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Active, not recruiting
1
22
US
Ixabepilone, (1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione, Azaepothilone B, BMS 247550, BMS-247550, BMS247550, Epothilone, Epothilone-B BMS 247550, Ixempra, Pharmacological Study, Temsirolimus, CCI 779, CCI-779, CCI-779 Rapamycin Analog, CCI779, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI)
Adult Solid Neoplasm
06/18
03/26
NCT03393741: Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

Terminated
N/A
5
US
Taxane, paclitaxel, nab-paclitaxel, docetaxel, Vinorelbine, vinca alkaloid, Ixabepilone, epothilone, Eribulin, halichondrins, Chemotherapy
University of Wisconsin, Madison, National Cancer Institute (NCI)
Breast Cancer, Breast Neoplasms
02/24
02/24
Halaven (eribulin mesylate) / Eisai
2020-001938-35: AIRE: Investigation of the immune response after chemotherapy treatment with Eribulin: A trial for female patients with advanced breast cancer. AIRE: Untersuchung der Immunantwort nach Behandlung mit der Chemotherapie Eribulin: Eine Studie für Patientinnen mit fortgeschrittenem Brustkrebs.

Not yet recruiting
4
84
Europe
Eribulin, Paclitaxel, Paclitaxel Albumin-Bound, Capecitabine, Vinorelbine, Solution for injection, Concentrate for solution for infusion, Powder for solution for infusion, Tablet, Halaven, Paclitaxel, nab-Paclitaxel, Capecitabine, Vinorelbine
Institut für Frauengesundheit GmbH, Institut für Frauengesundheit (IFG) GmbH
Female patients diagnosed with HER2 negative advanced breast cancer, which had received at least one previous chemotherapy Patientinnen, die mit einem HER2 negativen Brustkrebs im fortgeschrittenem Stadium diagnostiziert wurden und zuvor mindestens eine Chemotherapie erhielten., Female patients which were diagnosed with advanced breast cancer. The tumor should not have a certain marker (HER2) on its surface (HER2 negative breast cancer). Patientinnen, die mit einem Brustkrebs im fortgeschrittenem Stadium diagnostiziert wurden. Den Tumorzellen fehlt ein bestimmter Marker (HER2) auf der Oberfläche (HER2-negativer Brustkrebs)., Diseases [C] - Cancer [C04]
 
 
EPIC, ChiCTR2000038832: A multicenter, exploratory study of Eribulin combined with Pyrotinib in patients with advanced HER2-positive breast cancer who have previously used Taxanes and are resistant to Herceptin

Recruiting
4
50
 
Eribulin combine Pyrotinib
The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University, Self-funded
Breast cancer
 
 
ChiCTR2100048468: A real-world study of the efficacy and safety of Eribulin in different subtypes of advanced breast cancer

Recruiting
4
150
 
Eribulin
Shandong Cancer Hospital; Shandong Cancer Hospital, self-raised
breast cancer
 
 
ChiCTR2100051610: Single-center clinical study of the effectiveness and completeness of eribulin in combination with small molecule complexine kinase inhibitors for advanced solid tumors

Not yet recruiting
4
40
 
Chemotherapy + Targeted
Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, Wu Jieping Medical Foundation (Clinical Research Special Grant Fund)
Tumor patients
 
 
AIRE, NCT05033769: Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer

Recruiting
4
82
Europe
Eribulin Injection [Halaven], Eribulin, Paclitaxel injection, Paclitaxel
Institut fuer Frauengesundheit, Eisai GmbH
Breast Cancer Female, Neoplasm, Breast, Breast Cancer Metastatic
07/23
09/23
ChiCTR2100052828: Multicenter, randomized study of eribulin plus capecitabine versus capecitabine in HER2-negative patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes

Recruiting
4
320
 
Eribulin mesilate 1.4 mg/m^2 intravenously over 2-5 minutes on days 1 and 8 of every 21-day cycle, in combine with Capecitabine tablet 1000 mg/m^2 orally bid for days 1 to 14 of every 21-day cycle ;Capecitabine tablet 1250 mg/m^2 orally bid for days 1 to 14 of every 21-day cycle
Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences, Eisai China lnc.
Breast cancer
 
 
ChiCTR2300078142: Fruquintinib combined with eribulin as 2nd line or above treatment in patients with HR positive HER-2 negative breast cancer

Recruiting
4
40
 
fruquintinib; Eribulin
Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, Self-funded
Breast Cnacer
 
 
ChiCTR2500102304: The effect of prolonged analgesia with Eribulin on postoperative pain and knee function in patients undergoing total knee arthroplasty: a prospective randomized controlled study.

Not yet recruiting
4
80
 
Oral administration of Erichoxib (100mg per dose, twice a day) 1 day before surgery, followed by 100mg of Erichoxib 2 hours after surgery, then 100mg of Erichoxib every 12 hours.; Oral placebo (100mg per dose, 2 doses per day) 1 day before surgery, followed by 100mg of Eribulin 2 hours after surgery, and then 100mg of Eribulin every 12 hours.
Xi'an Honghui hospital; Xi'an Honghui hospital, Self-raised
Osteoarthritis of knee joint
 
 
ACTRN12607000176460: A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 versus Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes

Recruiting
3
1100
 
Eisai, Eisai
Breast Cancer Locally Advanced or Metastatic
 
 
ACTRN12612000100897: Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

Active, not recruiting
3
540
 
Eisai Limited, Eisai Limited
Non-small cell lung cancer
 
 
OlympiAD, NCT02000622 / 2013-005137-20: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Checkmark Approved for HER2 - locally-advanced or metastatic breast cancer with gBRCAm
Apr 2019 - Apr 2019: Approved for HER2 - locally-advanced or metastatic breast cancer with gBRCAm
Checkmark Approval
Jan 2019 - Apr 2019: Approval
Checkmark Approved for unresectable/recurrent BRCA-mutated, HER2-ve breast cancer (based on OlympiAD trial)
More
Active, not recruiting
3
302
Europe, Japan, US, RoW
Olaparib, Physician's choice chemotherapy
AstraZeneca, Myriad Genetic Laboratories, Inc., Merck Sharp & Dohme LLC
Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
12/16
12/25
TULIP, NCT03262935 / 2017-001994-18: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Completed
3
437
Europe, Canada, US, RoW
(vic-)trastuzumab duocarmazine, SYD985, Trastuzumab vc-seco-DUBA, Physician's choice, Lapatinib (Lap), Capecitabine (Cap), Trastuzumab (T), Vinorelbine (Vino), Eribulin (Eri)
Byondis B.V.
Metastatic Breast Cancer
03/21
06/22
2018-004211-42: A clinical study to compare treatment of Balixafortide in combination with Eribulin or Eribulin alone, in patients with no protein HER2 present in their cells and had locally repeated or spread breast cancer.

Not yet recruiting
3
384
RoW, Europe
Balixafortide, Halaven, POL6326, Concentrate for solution for infusion, Solution for injection, Halaven
Polyphor Ltd., Polyphor Ltd.
Patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer, Patients with breast cells that do not have on their surface the HER2 protein (receptor for the Human epidermal growth factor receptor 2) and that have locally repeated or spread breast cancer, Diseases [C] - Cancer [C04]
 
 
FORTRESS, NCT03786094: Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

Terminated
3
432
Europe, US, RoW
Eribulin, Eribulin Injection [Halaven], Balixafortide, POL6326
Spexis AG
Metastatic Breast Cancer, Locally Recurrent Breast Cancer
10/21
10/21
2020-005620-12: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Cancer Ensayo clínico de Dato-DXd en comparación con la quimioterapia de elección del investigador en cáncer de mama inoperable o metastásico, con receptores hormonales positivos HER2 negativo.

Not yet recruiting
3
700
Europe
Datopotamab deruxtecan, Eribulin mesylate, Capecitabine, Gemcitabine, Vinorelbine, DS-1062a, Powder for concentrate for solution for infusion, Solution for injection/infusion, Film-coated tablet, Powder for solution for infusion, HALAVEN, Capecitabine Accord, Bendacitabin, Bendarelbin
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy Cáncer de mama inoperable o metastásico, con receptores hormonales positivos, HER2 negativo, tratado una o dos líneas previas de quimioterapia sistémica, Breast Cancer Cáncer de mama, Diseases [C] - Cancer [C04]
 
 
DESTINY-Breast04, NCT03734029 / 2018-003069-33: Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed []

Jan 2023 - Jun 2023: Regulatory decision in China for 3L HER2-low breast cancer (based on DESTINY-Breast04 trial)
Jan 2023 - Mar 2023: Regulatory decision in Japan for 3L HER2-low breast cancer (based on DESTINY-Breast04 trial)
Checkmark Approved in EU as monotherapy for HER2 low breast cancer based on DESTINY-Breast04 trial
Jan 2023 - Jan 2023: Approved in EU as monotherapy for HER2 low breast cancer based on DESTINY-Breast04 trial
Checkmark Approved in Canada for the treatment of 2L HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer
More
Active, not recruiting
3
557
Europe, Canada, Japan, US, RoW
Trastuzumab deruxtecan (DS-8201a), DS-8201a, Capecitabine, Eribulin, Gemcitabine, Paclitaxel, Nab-paclitaxel
Daiichi Sankyo, Daiichi Sankyo Co., Ltd., AstraZeneca
Breast Cancer
01/22
10/25
EMERALD, NCT03264547: A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Recruiting
3
480
Japan
Pertuzumab, Perjeta, Trastuzumab, Herceptin, Docetaxel, Taxotere, Paclitaxel, Taxol, Eribulin, Halaven
Japan Breast Cancer Research Group, Eisai Co., Ltd.
Breast Cancer
04/22
10/23
EVER-132-002, NCT04639986: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Active, not recruiting
3
331
RoW
Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, GS-0132, Eribulin Mesylate Injection, Halaven, Capecitabine Oral Product, Xeloda, Gemcitabine Injection, Gemzar, Vinorelbine injection, Navelbine
Gilead Sciences, Iqvia Pty Ltd, Medidata Solutions, Parexel
Metastatic Breast Cancer
12/25
12/25
NCT05134194: A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer

Terminated
3
1
RoW
Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine, Capecitabine/eribulin/gemcitabine/vinorelbine
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Triple Negative Breast Cancer
01/22
12/22
NCT06857305: Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial

Enrolling by invitation
3
192
RoW
Eribulin biweekly regimen, Eribulin standard regimen
Ma Fei，MD
Breast Cancer Metastatic
07/26
07/26
NCT06143553: Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

Recruiting
3
168
RoW
Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate injection, Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection, Paclitaxel (albumin-bound)
Shanghai Yizhong Pharmaceutical Co., Ltd.
Metastatic Breast Cancer (MBC)
12/25
12/25
NCT05346861: Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Recruiting
3
240
RoW
Trastuzumab plus chemotherapy, Trastuzumab in combination with pyrotinib plus chemotherapy
Fudan University
HER2-positive Breast Cancer, Metastatic Breast Cancer
10/23
10/24
OptiTROP-Breast01, NCT05347134: SKB264 Injection Vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Active, not recruiting
3
254
RoW
SKB264, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Triple Negative Breast Cancer
11/23
03/25
B2023-686-01, NCT06268652: Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer

Recruiting
3
302
RoW
Organoid-guided personalized treatment, OGPT, Gemcitabine, Gemzar, Capecitabine, Xeloda, Vinorelbine, Navelbine, Eribulin, Halaven
Sun Yat-sen University
Breast Cancer, Refractory Breast Carcinoma
02/26
01/28
SYSKY-2023-1016-01, NCT06255392: Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Not yet recruiting
3
200
RoW
Fluzoparib, Apatinib Mesylate, Capecitabine tablets, Vinorelbine Tartrate Oral, Eribulin mesylate injection, Gemcitabine Hydrochloride, Paclitaxel-albumin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
03/31
03/31
RESQ, jRCTs011180026: A Phase III, Open Label, Randomized, Controlled, Multicenter Study, comparing Eribulin with S1, to assess Health-related Quality of Life (HRQoL) in the Treatment of Her2 negative Metastatic Breast Cancer Patients

Completed
3
330
Japan
Halaven (eribulin mesylate) - Eisai, Teysuno (gimeracil/oteracil/tegafur) - Nordic Group, Otsuka
CSPOR-BC, Eisai Co. Ltd.
metastatic breast cancer
 
 
SKB264-Ⅲ-11, NCT06279364: A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Recruiting
3
524
RoW
SKB264, Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, Carboplatin
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Triple Negative Breast Cancer
07/26
07/26
NCT06343948: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer

Active, not recruiting
3
383
RoW
BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, Eribulin, Vinorelbine, Gemcitabine, Capecitabine
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
HR+HER2- Breast Cancer
05/26
05/26
NCT06382142: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Recruiting
3
406
RoW
BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, Eribulin, Vinorelbine, Gemcitabine, Capecitabine
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Triple-Negative Breast Cancer
06/26
06/26
INVINCIBLE-3, NCT06263231: A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas

Recruiting
3
333
Europe, Canada, US
INT230-6, Eribulin, Trabectedin, Pazopanib
Intensity Therapeutics, Inc., Premier Research Group plc
Sarcoma,Soft Tissue
12/27
12/28
NCT06383767: A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Recruiting
3
378
RoW
ESG401, Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)
Qilu Pharmaceutical Co., Ltd.
Metastatic Breast Cancer
06/27
07/28
NCT06519370: FDA018-ADC Vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Recruiting
3
350
RoW
FDA018-ADC, FDA018-Antibody-drug Conjugate, Eribulin, Halaven, Capecitabine, Xeloda, Gemcitabine, Gemzar, Vinorelbine, Navelbine
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Triple Negative Breast Cancer
08/26
06/27
EmpowHER-303, NCT06435429: A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Recruiting
3
550
Europe, Canada, Japan, US, RoW
Zanidatamab, Trastuzumab, Eribulin, Vinorelbine, Gemcitabine, Capecitabine
Jazz Pharmaceuticals
Metastatic HER2-positive Breast Cancer
09/28
11/31
DETECT V, NCT02344472 / 2014-002249-22: Detect V / CHEVENDO (Chemo vs. Endo)

Active, not recruiting
3
271
Europe
pertuzumab, Perjeta®, Trastuzumab, Herceptin®, Capecitabine, Paclitaxel, Vinorelbine, Docetaxel, Exemestane, Letrozole, Anastrozole, Fulvestrant, Ribociclib, Kisqali®, nab-Paclitaxel, eribulin, leuprorelin, goserelin
Prof. Wolfgang Janni, Roche Pharma AG, Novartis Pharmaceuticals, Eisai GmbH, Celgene Corporation
Metastatic Breast Cancer
01/25
01/25
TROPiCS-02, NCT03901339 / 2018-004201-33: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Jul 2023 - Dec 2023: Regulatory decision in EU for HR+/HER2 breast cancer
Checkmark Approved for unresectable, locally advanced or metastatic HR+, HER2-ve metastatic breast cancer based on data from TROPiCS-02 study
Feb 2023 - Feb 2023: Approved for unresectable, locally advanced or metastatic HR+, HER2-ve metastatic breast cancer based on data from TROPiCS-02 study
Checkmark EMA validated MAA for Trodelvy for pre-treated HR+/HER2- metastatic breast cancer
Jan 2023 - Jan 2023: EMA validated MAA for Trodelvy for pre-treated HR+/HER2- metastatic breast cancer
More
Completed
3
543
Europe, Canada, US
Sacituzumab Govitecan-hziy, IMMU-132, GS-0132, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Gilead Sciences
Metastatic Breast Cancer
10/23
10/23
ANGLeD, NCT03613181: ANG1005 in Leptomeningeal Disease From Breast Cancer

Not yet recruiting
3
150
NA
ANG1005, paclitaxel trevatide, Physician's Best Choice, capecitabine, eribulin, high-dose IV methotrexate.
Angiochem Inc
Leptomeningeal Carcinomatosis, Leptomeningeal Metastases, Brain Metastases, HER2-negative Breast Cancer
12/24
12/24
BCTOP-T-M02, NCT05760378: Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Recruiting
3
223
RoW
Famitinib, Camrelizumab, nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin
Fudan University
Triple-Negative Breast Cancer
01/25
01/27
SHR-A1811-III-306, NCT05814354: SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial

Recruiting
3
530
RoW
SHR-A1811, Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel
Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer
01/25
06/26
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Not yet recruiting
3
400
RoW
JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Breast Cancer
04/25
03/29
NCT06889688: Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer

Active, not recruiting
3
246
RoW
Camrelizumab+Apatinib+Eribulin, Physician's choice chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer Stage IV
09/30
03/31
NCT06957886: A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

Recruiting
3
564
RoW
BL-M07D1, Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
HER2-low Breast Cancer
05/27
12/27
BRIA-ABC, NCT06072612: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting
3
404
US
SV-BR-1-GM, Part of the Bria-IMT regimen, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
BriaCell Therapeutics Corporation
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
01/26
06/26
TQB2930-III-01, NCT07047365: TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Not yet recruiting
3
416
RoW
TQB2930+ chemotherapy, Trastuzumab+ chemotherapy
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
HER2-positive Advanced Breast Cancer
06/28
12/28
BCTOP-T-M03, NCT05954442: Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

Recruiting
3
203
RoW
Everolimus, Afinitor, Investigator's Choice of Chemotherapy, ICC
Fudan University
Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation
08/25
08/26
TROPION-Breast01, NCT05104866 / 2020-005620-12: A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy

Jan 2024 - Dec 2024: Data from TROPION-Breast01 trial for inoperable or metastatic HR+, HER2- breast cancer
Hourglass Feb 2024 - Mar 2024 : Q4 FY'23 - Acceptance of regulatory submission in US for 2-3L HR+, HER2- breast cancer (based on TROPION-Breast01 trial)
Active, not recruiting
3
732
Europe, Canada, Japan, US, RoW
Dato-DXd, Datopotamab deruxtecan (Dato-DXd, DS-1062a), Capecitabine, Gemcitabine, Eribulin, Eribulin Mesylate, Vinorelbine
AstraZeneca, Daiichi Sankyo
Breast Cancer
07/24
12/25
BCTOP-T-M01, NCT05806060: Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer

Recruiting
3
192
RoW
VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine, Bevacizumab (BP102), nab-paclitaxel, with maintenance of capecitabine, Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1, VEGFR and TPC
Fudan University
Triple-Negative Breast Cancer
08/25
02/26
NCT06732323: A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Not yet recruiting
3
504
RoW
ESG401, Investigator's Choice Chemotherapy
Qilu Pharmaceutical Co., Ltd.
Triple-Negative Breast Cancer (TNBC)
06/27
07/28
TROPION-Breast02, NCT05374512 / 2021-005223-21: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy

Hourglass May 2025 - Jun 2025 : Initial data for 1L PD-1/PD-L1 ineligible TNBC
Jan 2024 - Dec 2024: Acceptance of regulatory submission for 1L TNBC (based TROPION-Breast02 trial)
Active, not recruiting
3
644
Europe, Canada, Japan, US, RoW
Dato-DXd, Datopotamab deruxtecan (Dato-DXd, DS-1062a), Paclitaxel, Nab-paclitaxel, Carboplatin, Capecitabine, Eribulin mesylate
AstraZeneca, Daiichi Sankyo
Breast Cancer
12/25
12/25
SKB264-Ⅲ-10, NCT06081959: Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

Recruiting
3
376
RoW
SKB264, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Metastatic Breast Cancer
03/26
12/27
ALPHABET, NCT05063786 / 2020-005639-65: Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer

Active, not recruiting
3
27
Europe
Trastuzumab, Herceptin, Alpelisib, Piqray, Fulvestrant, Faslodex, Vinorelbine, Navelbine, Capecitabine, Xeloda, Eribulin, Halaven
Spanish Breast Cancer Research Group, ETOP IBCSG Partners Foundation, Breast International Group, Novartis Pharmaceuticals
Advanced Breast Cancer
06/25
06/25
SWOG S1937, NCT04579224: Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Recruiting
3
184
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Eribulin Mesylate, B1939 Mesylate, E7389, ER-086526 Mesylate, Halaven, Halichondrin B Analog, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU 132, IMMU-132, IMMU132, RS7 SN38, RS7-SN38, RS7SN38, Sacituzumab Govitecan-hziy, Trodelvy
National Cancer Institute (NCI)
Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
08/30
08/30
2ND-STEP, jRCTs031190152: JCOG1802: A randomized phase II trial of 2nd line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib

Active, not recruiting
2
120
Japan
Yondelis (trabectedin) - Otsuka, PharmaMar, Valeo Pharma, J&J, Halaven (eribulin mesylate) - Eisai, Votrient (pazopanib) - Novartis, BeiGene
Oita University Hospital, National Cancer Center Japan,Japan Agency for Medical Research and Development
Advanced soft tissue sarcoma
 
 
2012-003505-10: Gemcitabine and Eribulin as first line treatment of advanced triple-negative breast cancer. Gemcitabina ed Eribulina come trattamento di prima linea nel carcinoma mammario triplo-negativo in fase avanzata.

Ongoing
2
83
Europe
GEMCITABINA HOS.IT*INF FL 1G, HALAVEN*EV 6FL 2ML 0,44MG/ML, GEMCITABINA HOS.IT*INF FL 1G, HALAVEN*EV 6FL 2ML 0,44MG/ML
GRUPPO ONCOLOGICO ITALIANO DI RICERCA, EISAI Srl
Locally recurrent or metastatic triple negative breast cancer. Pazienti con tumore della mammella triplo negativo con recidiva locale o metastatico.
 
 
2017-003621-15: A Phase II study of a Combination of Eribulin and capecitabiNe in second line Treatment after the failure of gemcitabine/abraxane first line in advanced pancreatic cancer Studio di Fase II di eribulina in combinazione con capecitabina per il trattamento di seconda linea in pazienti affetti da carcinoma pancreatico avanzato dopo fallimento di terapia di prima linea con gemcitabina/abraxane.

Not yet recruiting
2
25
Europe
HALAVEN, Capecitabina accord 150, Capecitabina Accord 500, [-], Solution for infusion, Film-coated tablet, HALAVEN - 0.44MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 2ML 6 FLACONCINI, CAPECITABINA ACCORD - 150 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PVDC/ALU) - 120 COMPRESSE, CAPECITABINA ACCORD - 500 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PVDC/ALU) - 120 COMPRESSE
AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA, EISAI srl
advanced pancreatic cancer tumore del pancreas avanzato, advanced pancreatic cancer tumore del pancreas avanzato, Diseases [C] - Cancer [C04]
 
 
2017-004652-35: Second line ERIbulin followed by CApecitabine or the reverse sequence in HER2-negative Metastatic Breast Cancer (MBC) patients: a randomized phase II study – ERICA trial ERIbulina in seconda linea seguita da CApecitabina o sequenza inversa in pazienti con carcinoma mammario metastatico (MBC) HER2-negativo: uno studio randomizzato di fase II – Studio ERICA

Ongoing
2
150
Europe
HALAVEN, Xeloda, [Eribulina], [Capecitabina], Solution for injection, Film-coated tablet, HALAVEN - 0.44MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 2ML 6 FLACONCINI, XELODA - 500 MG 120 COMPRESSE FILMRIVESTITE IN BLISTER USO ORALE
CONSORZIO ONCOTECH, EISAI S.r.l.
HER2-negative Metastatic Breast Cancer Carcinoma mammario metastatico HER2-negativo, Metastatic Breast Tumour Tumore al seno metastatico, Diseases [C] - Cancer [C04]
 
 
NCT03051659: A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer

Checkmark In combination with eribulin in HR+ve, HER2-ve mBC
Sep 2020 - Sep 2020: In combination with eribulin in HR+ve, HER2-ve mBC
Completed
2
90
US
Eribulin Mesylate, Halaven, Pembrolizumab, Keytruda
Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC
Breast Cancer
10/18
09/23
2018-004571-12: Trial in advanced Solitary Fibrous Tumor (SFT) Studio clinico nel Tumore Fibroso Solitario (TFS)

Not yet recruiting
2
20
Europe
Eribulina, [30058], Solution for injection, HALAVEN - 0.44MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 2ML 6 FLACONCINI
ITALIAN SARCOMA GROUP, Eisai Italy
Advanced Solitary Fibrous Tumor (SFT) Tumore Fibroso Solitario in fase avanzata, Advanced Solitary Fibrous Tumor (SFT) Tumore Fibroso Solitario in fase avanzata, Diseases [C] - Cancer [C04]
 
 
2020-004909-32: Can treatment with Eribulin chemotherapy restore the sentivity in cancertissue in subsequent treatment with antihormon treatment? A study for patients with ER positive, HER2 normal breast cancer. Kan behandling med kemoterapien eribulin genskabe kræftvævets følsomhed for efterfølgende antihormonbehandling. Et studie til patienter med ER positiv, HER2 normal brystkræft.

Not yet recruiting
2
42
Europe
Halaven, Concentrate and solvent for solution for infusion, Tablet, Halaven, Aromasin
Department of Oncology, Department of oncology, University Hospital of Aarhus, Skejby
Metastatic breast cancer with estrogene positive and HER2 normal/negative subtype. Metastatisk brystkræft med østrogenreceptor positive og HER2 normal/negative HER2 receptor status., Breast cancer with has spred to other organs with is sentitive to estrogen and has a normal HER2 receptor status. Brystkræft med spredning til andre organer som er østrogen receptor positive og har HER2 normal udtryk ved immunhistokemi., Diseases [C] - Cancer [C04]
 
 
2017-004324-30: Clinical Trial to study the effect of the treatment with eribulin and endocrine therapy in metastatic breast cancer patients Ensayo clínico para estudiar el efecto de tratamiento con eribulina y terapia endocrina en pacientes con cáncer de mama avanzado

Not yet recruiting
2
60
Europe
Solution for injection, HALAVEN
Medica Scientia Innovation Research (MEDSIR), EISAI FARMACEUTICA S.A.
Luminal Metastatic Breast Cancer Cáncer de mama metastásico luminal, Metastatic Breast Cancer Cáncer de mama metastásico, Diseases [C] - Cancer [C04]
 
 
NCT02623972: A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Active, not recruiting
2
22
US
Eribulin, Halaven, B1939 mesylate, Adriamycin, Doxorubicin, Cyclophosphamide, Cytoxan®, Neosar®
Dana-Farber Cancer Institute, Eisai Inc.
Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
05/21
12/26
NCT04624711: Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

Recruiting
2
40
RoW
Eribulin Mesylate, Halaven, Anlotinib hydrochloride, Anlotinib
The First Affiliated Hospital with Nanjing Medical University
HER2-negative Breast Cancer
06/22
12/22
TEMPLATE, NCT04913571: Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study

Not yet recruiting
2
265
RoW
Eribulin, Tislelizumab
Fudan University
Triple Negative Breast Cancer
06/22
06/23
NCT03331250: Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

Active, not recruiting
2
13
US
Eribulin, Halaven
Massachusetts General Hospital, Eisai Inc.
Angiosarcoma, Epithelioid Hemangioendothelioma
07/23
05/25
NCT04517292: Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)

Not yet recruiting
2
160
RoW
Eribulin,cisplatin, Gemcitabine,cisplatin
Fudan University
Breast Cancer
07/22
10/22
Immuno2020-01, NCT04303741: A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

Active, not recruiting
2
46
RoW
Camrelizumab, Apatinib, Eribulin, Eribulin Mesylate
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
11/22
08/23
SAFIR02_Breast, NCT02299999 / 2013-001652-36: - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Active, not recruiting
2
1460
Europe
AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, ARRY-142866, Vandetanib, CAPRELSA, Bicalutamide, Casodex, Olaparib, Lynparza, Anthracyclines, Doxorubicin, Epirubicin, liposomal doxorubicin, Taxanes, paclitaxel, docetaxel, cyclophosphamide, Novatrex, Imeth, DNA intercalators, capecitabine, 5-FU, gemcitabine, Methotrexate, vinca alkaloids, vinorelbine, vinblastine, vincristine, Platinum based chemotherapies, Platinum, carboplatin, cisplatin, Bevacizumab, Avastin, Mitomycin C, Ametycine, Eribulin, Halaven, MEDI4736
UNICANCER, Fondation ARC, AstraZeneca
Metastatic Breast Cancer
12/22
12/25
NCT05546255: Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Recruiting
2
40
RoW
Eribulin Mesylate, Lobaplatin
Chinese Academy of Medical Sciences
Triple Negative Breast Cancer
12/22
12/23
 

Download Options